Sharklet

Sharklet
Name	Sharklet Technologies
Type	Private
Founded	2007
Founder	Gautam Chandarana
Headquarters	Durham, North Carolina
Products	Sharklet antimicrobial surface pattern
Industry	Biotechnology, Materials science

Sharklet is a biomimetic surface technology inspired by the skin microtopography of sharks and designed to inhibit microbial adhesion and biofilm formation. Developed in the early 21st century, the pattern has been investigated across healthcare, consumer products, and maritime sectors, drawing attention from researchers at institutions such as Harvard University, Duke University, and North Carolina State University. It has intersected with corporate partners, regulatory bodies, and standards organizations during efforts to commercialize antimicrobial surface solutions.

Overview

Sharklet is a micropatterned surface engineered to reduce surface colonization by organisms including Staphylococcus aureus, Pseudomonas aeruginosa, and other clinically relevant bacteria, with claimed applications in hospitals, aircraft interiors, and shipping infrastructure. The concept originates from biomimicry research linking shark dermal denticles observed by marine biologists and engineers at universities such as University of Florida and Scripps Institution of Oceanography to antifouling strategies employed in naval architecture and ocean engineering. Early literature and patents involved collaborations among academic inventors, venture-funded startups, and partners from National Science Foundation grant programs.

Design and Technology

The technology employs a deterministic micropattern composed of repeating rectangular ribs and platelets at micron-scale dimensions, fabricated using methods drawn from microfabrication and photolithography practiced in cleanrooms at facilities like MIT and Stanford University. Manufacturing approaches have included injection molding, roll-to-roll embossing, and polymer replication techniques common to 3M and DuPont production lines. Materials used in prototypes range from medical-grade polymers to thermoplastics comparable to those used by Johnson & Johnson and Medtronic for device housings. The design rationale integrates surface energy modulation and topographic deterrence, concepts examined alongside work from National Institutes of Health funded biofilms research and standards by ASTM International.

Applications

Proposed and explored applications include integration into medical device surfaces such as catheter housings used in Centers for Disease Control and Prevention-monitored healthcare settings, high-touch surfaces in Johns Hopkins Hospital-type environments, consumer electronics housings similar to products from Apple Inc. and Samsung Electronics, and ship hull coatings evaluated by United States Navy research programs. Trials and pilot projects have also targeted dental tools used in American Dental Association-aligned practices, food contact surfaces inspected by USDA-aligned processors, and public transport interiors in collaboration with transit authorities like Metropolitan Transportation Authority.

Efficacy and Research

Peer-reviewed studies from laboratories at institutions such as Duke University, North Carolina State University, and University of California, San Diego have investigated reductions in bacterial attachment and biofilm formation, often benchmarking against flat control surfaces and comparing with chemical antimicrobials evaluated by Food and Drug Administration guidance. Reports cited variable log-reductions in colony-forming units for organisms including Escherichia coli, Candida albicans, and Enterococcus faecalis, while marine antifouling work compared barnacle settlement metrics against coatings tested in Woods Hole Oceanographic Institution-associated field sites. Independent testing labs accredited by International Organization for Standardization have applied protocols derived from ISO 22196 and ASTM G21, though study outcomes depend on inoculum, shear conditions, and surface chemistry variables.

Regulatory and Commercialization History

Commercialization efforts involved licensing agreements, venture capital rounds, and strategic partnerships with industry players such as medical device companies and surface manufacturers active in Boston Consulting Group-modeled markets. Regulatory interactions included discussions with the Food and Drug Administration regarding claims allowable for non-leaching, passive antimicrobial surfaces and notifications to agencies analogous to Environmental Protection Agency processes for antifouling marine products. Market entry strategies referenced procurement channels in healthcare systems like Mayo Clinic and supply chain integration with distributors familiar to McKesson Corporation and Cardinal Health.

Criticisms and Limitations

Critiques have focused on the specificity of efficacy against diverse microbes, dependence on fabrication quality, and challenges scaling from laboratory to field environments documented by reviewers at Nature Reviews Microbiology and commentators from The Lancet. Limitations include sensitivity to surface contamination by organic films, potential manufacturing cost barriers compared with commodity plastics from BASF and ExxonMobil Chemical, and regulatory constraints on labeling and performance claims enforced by agencies such as the Federal Trade Commission. Skeptics also highlight the need for long-term, randomized studies in clinical settings similar to trials coordinated by Cochrane to substantiate infection-rate reductions.

Category:Biomimetics Category:Surface engineering Category:Materials science